← All trials
NCT03565276
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2018
- Primary completion
- Dec 31, 2018
- Completion date
- Dec 31, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 83
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TorontoLead sponsor
- University of TorontoCollaborator
- University of TorontoCollaborator
- University of TorontoOverall official - principal investigator
- University of TorontoReponsible party - principal investigator
- University of WaterlooCollaborator
- Sinai Health SystemCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.